Cristina P. Rodriguez

Cristina P. Rodriguez

Auto-generated profile, based on publicly available information

Cristina P. Rodriguez

Department of Medicine, Division of Medical Oncology, University of Washington/Fred Hutchinson Cancer Center, Seattle, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CRCristina P. Rodriguez
Cristina P. Rodriguez
QWQian (Vicky) Wu
Qian (Vicky) Wu
JVJenna Voutsinas
Jenna Voutsinas
JFJonathan R. Fromm
Jonathan R. Fromm
XJXiuyun Jiang
Xiuyun Jiang
RMRenato Martins
Renato Martins
Purpose: This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic squamous cell carcinomas of the head and neck (HN), and salivary gland cancer (SGC). Patients and Methods: Patients with progressing incurable HN and SGC, Eastern Cooperative Oncology Group (ECOG) ≤1, no prior immunotherapy, RECIST1.1 measurable disease, and normal organ function were eligible. Pembrolizumab 200 mg was given intravenous every 21 days, and vorinostat 400 mg given orally 5 days on and 2 days off during each 21-day cycle. Primary endpoints were safety and objective response rates. Results: From November 2015 to August 2017, 25 patients with HN and 25 SGC were enrolled. Median age was 61 (range, 33–86) years, 39 (78%) were male, 21 (62%) were never smokers, and 27 (54%) had ECOG 0. In HN, 13 (52%) were p16+ oropharynx. Most common SGC histologies were adenoid cystic 12 (48%), acinic cell 3 (12%), and mucoepidermoid 3 (12%). Adverse events (AEs) in all patients were: 27 (54%) with grade ≥ 1 and 18 (36%) with grade ≥ 3. The most common AEs in all patients were renal insufficiency in seven, (14%), fatigue in six, (12%), and nausea in three (6%). There were three (12%) deaths on study. Responses in HN were complete response (CR) 0, partial response (PR) eight (32%), and stable disease (SD) five (20%). Efficacy in SGCs was CR 0, PR four (16%) in one lymphoepithelioma-like carcinoma, two acinic cell, one adenoid cystic, and SD 14 (56%). In the HN group, median follow-up (mFUP) was 12.6 months, median overall survival (mOS) was 12.6 months, and median progression-free survival (mPFS) was 4.5 months. In SGC, mFUP was 13.1 months, mOS was 14.0 months, and mPFS was 6.9 months. Conclusions: This combination demonstrated activity in HN, with fewer responses in SGC. Toxicities were higher than reported with pembrolizumab alone.

28 December 2017 in Head & Neck
Verified
Journal Article
Closed access
PDF file
CRCristina P. Rodriguez
Cristina P. Rodriguez
RMRenato G. Martins
Renato G. Martins
CBChristina Baik
Christina Baik
LCLaura Q. Chow
Laura Q. Chow
RSRafael Santana‐Davila
Rafael Santana‐Davila
KEKeith D. Eaton
Keith D. Eaton

29 October 2014 in Head & Neck
Verified
Journal Article
Closed access
CRCristina P. Rodriguez
Cristina P. Rodriguez
DADavid J. Adelstein
David J. Adelstein
LRLisa A. Rybicki
Lisa A. Rybicki
PSPanayiotis Savvides
Panayiotis Savvides
JSJerrold P. Saxton
Jerrold P. Saxton
DIDenise I. Ives
Denise I. Ives

18 April 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
MGMargaret K. Guerriero
Margaret K. Guerriero
MRMary W. Redman
Mary W. Redman
KBKelsey K. Baker
Kelsey K. Baker
RMRenato G. Martins
Renato G. Martins
KEKeith Eaton
Keith Eaton
CRCristina P. Rodriguez
Cristina P. Rodriguez

4 December 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
KKKedar Kirtane
Kedar Kirtane
CRCristina P. Rodriguez
Cristina P. Rodriguez
Patients who undergo upfront curative intent resection for locally advanced squamous cell carcinomas and who have adverse pathologic features benefit from adjuvant therapy. Concurrent cisplatin based chemoradiation is an established standard of care endorsed by national guidelines. Controversy now exists on the applicability of this strategy to the good risk human papilloma virus (HPV) related oropharynx cancer (OPC) patient. Ongoing clinical studies are exploring therapeutic de-escalation in the postoperative setting for this distinct patient population. The introduction of immune checkpoint inhibitors to the therapeutic armamentarium for recurrent/metastatic head and neck cancer patients has led to clinical investigation of incorporation of PD-1 inhibition in the postoperative setting.

2 September 2022 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
CRCristina P Rodriguez
Cristina P Rodriguez
HKHyunseok Kang
Hyunseok Kang
JGJessica L Geiger
Jessica L Geiger
BBBarbara Burtness
Barbara Burtness
CCChristine H Chung
Christine H Chung
SMShakun Malik
Shakun Malik
TP53 mutation is the most frequent genetic event in head and neck squamous cell carcinoma (HNSCC), found in more than 80% of patients with human papillomavirus–negative disease. As mutations in the TP53 gene are associated with worse outcomes in HNSCC, novel therapeutic approaches are needed for patients with TP53-mutated tumors. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issues of identifying and developing clinical trials for patients with TP53 mutations. Subcommittees, or breakout groups, were tasked with developing clinical studies in both the locally advanced and recurrent and/or metastatic (R/M) disease settings as well as considering signal-seeking trial designs. A fourth breakout group was focused on identifying and standardizing biomarker integration into trial design; this information was provided to the other breakout groups prior to the meeting to aid in study development. A total of 4 concepts were prioritized to move forward for further development and implementation. This article summarizes the proceedings of the Clinical Trials Planning Meeting with the goal of developing clinical trials for patients with TP53-mutant HNSCC that can be conducted within the National Clinical Trials Network.